USFDA successfully completes inspection at Bajaj Healthcare Vadodara facility

Published On 2022-11-18 07:45 GMT   |   Update On 2022-11-18 07:45 GMT

Thane: Bajaj Healthcare Limited (BHL), a manufacturer of APIs, Intermediates, and Formulations, has announced a successful competition of the first-ever pre-approval inspection of the United States Food and Drug Administration (USFDA) at its API facility located at Vadodara, Gujarat.

The inspection was held from November 14, 2022 to November 17, 2022.

"BHL is pleased to inform you that US Food and drug administration (USFDA) has conducted the pre-approval inspection of its API facility located at Vadodara, Gujarat, from November 14, 2022 to November 17, 2022," the company said in a BSE filing.
Advertisement
Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said, "I am happy to announce that we successfully completed the first-ever pre-approval USFDA inspection with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services and timely delivery to our clients."
Advertisement

Read also: Bajaj Healthcare enters highly regulated opiate processing business

Bajaj Healthcare Limited is a manufacturer of APIs, Intermediates, and Formulations established in 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which six units are dedicated to APIs, two units to Intermediates, and 1 unit for formulation. It has a strong presence globally in countries like Europe, the USA, Australia, Africa, the Middle East, and South America.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News